Literature DB >> 7908177

Toxicity of compound A in rats. Effect of increasing duration of administration.

C T Gonsowski1, M J Laster, E I Eger, L D Ferrell, R L Kerschmann.   

Abstract

BACKGROUND: An olefin called compound A (CF2 = C(CF3)OCH2F) results from the action of soda lime or Baralyme on sevoflurane. We have demonstrated that rats exposed to the olefin for 3 h died at or were injured by olefin concentrations lower than those previously reported to produce these effects. The present report examines the impact of duration of exposure to the olefin on such effects.
METHODS: Twenty-three groups of ten Wistar rats breathed 0, 12.5, 25, 50, 75, 100, 125, 150, 175, 200, 225, and 250 ppm of the olefin in oxygen for 6 or 12 h. Rats that survived were killed on day 1 or day 4 after breathing the olefin, and specimens of brain, kidney, lung, liver, and small intestine were obtained from all rats for examination by microscopy using hematoxylin and eosin stain and a stain (proliferating cell nuclear antigen) for cell growth (regeneration).
RESULTS: The lethal concentrations in 50% of rats equaled 203 +/- 4 ppm (mean +/- SE) for a 6-h exposure period and 127 +/- 9 ppm for a 12-h exposure period, and both values were less than the previously determined value of 331 +/- 7 ppm for a 3-h exposure period. Compared with results from control rats (those breathing oxygen for 6 h or 12 h), only renal and pulmonary injury were found. Pulmonary injury only occurred at near-lethal concentrations. Renal injury (defined as necrosis of the outer stripe of the outer medullary layer or corticomedullary junction necrosis) occurred at and above 25-50 ppm for 6-h and 12-h exposures, respectively, a result similar to that previously obtained with a 3-h exposure. Exposure to 25-50 ppm stimulated cell regeneration in a dose-related manner.
CONCLUSIONS: In rats, lethal concentrations of the olefin and concentrations producing severe renal injury are inversely related to the duration of exposure to the olefin, exceeding by two- to fourfold peak concentrations that can be obtained in clinical practice. The threshold concentrations for nephrotoxicity (i.e., minimal toxicity) equal concentrations that can be produced in clinical practice. However, even if these threshold effects in rats apply to humans, they probably would not alter renal function. Although dose-related, neither the lethal nor the toxic effects are simply a function of cumulative dose (concentration-time).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908177     DOI: 10.1097/00000542-199403000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  18 in total

Review 1.  Anaesthesia in the elderly. Special considerations.

Authors:  A G Jones; J M Hunter
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

2.  New volatile anaesthetics in cardiovascular anaesthesia: one step forward, two steps back?

Authors:  I R Thomson
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

3.  RE: Yuge O: Renal toxicity of compound A with sevoflurane anesthesia: the benefits of sevoflurane appear to outweight the risks (editorial).J. Anesth 11:1-2.

Authors:  Edmond I Eger; Jackie L Martin
Journal:  J Anesth       Date:  1997-12       Impact factor: 2.078

4.  Humidification during low-flow anesthesia in children.

Authors:  Yuri Nakae; Dai Horikawa; Keiko Tamiya; Akiyoshi Namiki
Journal:  J Anesth       Date:  1998-12       Impact factor: 2.078

Review 5.  The introduction of new drugs into anaesthetic practice: a perspective in pharmaceutical development and regulation.

Authors:  I Gilron
Journal:  Can J Anaesth       Date:  1995-06       Impact factor: 5.063

6.  Effect of sevoflurane anesthesia on the severity of renal histopathologic changes in rabbits pretreated with gentamicin: A controlled, investigator-blinded, experimental study.

Authors:  Azize Bestas; Mustafa Kemal Bayar; Nusret Akpolat; Mehmet Nihat Okuducu
Journal:  Curr Ther Res Clin Exp       Date:  2006-11

7.  Studies of the mechanism of nephrotoxicity of compound A in rats.

Authors:  J L Martin; L Kandel; M J Laster; R L Kerschmann; E I Eger
Journal:  J Anesth       Date:  1997-03       Impact factor: 2.078

Review 8.  Sevoflurance: approaching the ideal inhalational anesthetic. a pharmacologic, pharmacoeconomic, and clinical review.

Authors:  L Delgado-Herrera; R D Ostroff; S A Rogers
Journal:  CNS Drug Rev       Date:  2001

Review 9.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of sevoflurane.

Authors:  M Behne; H J Wilke; S Harder
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.